ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1133

Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis

Deepan Dalal1, Tingting Zhang 2 and Theresa Shireman 2, 1Brown University, Riverside, RI, 2Brown University, Providence, RI

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: DMARDs and health care cost, Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Health Services Research Poster II – ACR/ARP

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Biologic disease modifying agents (DMARDs) have become an integral part of rheumatoid arthritis (RA) treatment guidelines, but they are associated with a substantial increase in direct medical care costs. Given Medicare’s role in providing health care coverage to older adults, we assessed the impact biologic and conventional DMARDs have had on its drug expenditures.

Methods: We compiled six years (2012-17) of publicly available Medicare spending reports capturing DMARDs expenditures aggregated from Part B (infusions) and Part D (oral) claims. Data included: total expenditures (before rebates), beneficiary counts, and unit drug costs. We distinguished trends at the product level and subclasses, conventional and biologics DMARDs.

Results: Total spending for conventional DMARDs increased from $98 million to $579 million. Expenditures for methotrexate were surpassed by hydroxychloroquine expenditures in 2014-15 (Fig 1). The 6-fold increase in total spending was driven by increase in unit cost of drugs rather than increases in beneficiaries (738,000 to 1.13 million).

Total spending on biologic DMARDs rose from $4.3 billion to $10.0 billion with a more modest increase in the number of beneficiaries (252,225 to 353,960). Adalimumab expenditures rose from $674.8 million (2012) to $2.64 billion (2017): expenditures for etanercept ($1.76 billion) and rituximab ($1.75 billion) were the next highest (Fig 2).

Conclusion: Medicare expenditure for conventional agents increased dramatically but remained a fraction of the total spending (5.7%) on DMARDs when biologic agents were included. Rise in unit drug costs rather than increase in beneficiaries were often responsible for increased total spending. It is important to acknowledge that these products are also used for non-RA indications, and we were unable to account for manufacturers’ rebates. Further work is needed to determine if increases in DMARD are offset by cost reductions and lead to better patient outcomes.

Figure 1. Trends in Medicare spending for conventional DMARDs

Figure 2. Trends in Medicare spending on biologic DMARDs


Disclosure: D. Dalal, None; T. Zhang, None; T. Shireman, None.

To cite this abstract in AMA style:

Dalal D, Zhang T, Shireman T. Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/medicare-spending-2012-2017-on-disease-modifying-agents-commonly-used-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medicare-spending-2012-2017-on-disease-modifying-agents-commonly-used-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology